Identifying subgroups among poor prognosis patients with nonseminomatous germ cell cancer by tree modeling: A validation study

Annals of Oncology

Volumn 15, Issue 9, 2004, Pages 1400-1405

  van Dijk, M R ^a   Steyerberg, E W ^a   Stenning, S P ^b   Habbema, J D F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Germ cell cancer; Poor prognosis; Tree modelling; Validation

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; EXPERIMENTAL MODEL; HEALTH CARE ORGANIZATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; MEDICAL ASSESSMENT; META ANALYSIS; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TESTIS CANCER; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 4644325753     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh350     Document Type: Article

References (35)

1. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242-253.
2. Hartmann JT, Kanz L, Bokemeyer C. Diagnosis and treatment of patients with testicular germ cell cancer. Drugs 1999; 58: 257-281.
3. Sonneveld DJ, Hoekstra HJ, van der Graaf WT et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 2001; 91: 1304-1315.
4. Steele GS, Richie JP, Stewart AK, Menck HR. The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996. Cancer 1999; 86: 2171-2183.
5. de Wit R, Roberts JT, Wilkinson PM et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19: 1629-1640.
6. Hinton S, Catalano PJ, Einhorn LH et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 2003; 97: 1869-1875.
7. Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 1999; 17: 3450-3456.
8. Bokemeyer C, Harstrick A, Beyer J et al. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Semin Oncol 1998; 25: 24-32; discussion 45-28.
9. IGCCCG. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
10. Kaye SB, Mead GM, Fossa S et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998; 16: 692-701.
11. Fizazi K, Zelek L. Is one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. Ann Oncol 2000; 11: 133-149.
12. Motzer RJ, Mazumdar M, Gulati SC et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993; 85: 1828-1835.
13. Motzer RJ, Mazumdar M, Bajorin DF et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997; 15: 2546-2552.
14. Schmoll HJ, Kollmannsberger C, Metzner B et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003; 21: 4083-4091.
15. Motzer RJ, Sheinfeld S. Poor-risk testicular cancer and high-dose chemotherapy. J Clin Oncol 2003; 21: 4073-4074.
16. Kollmannsberger C, Nichols C, Meisner C et al. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol 2000; 11: 1115-1120.
17. Marshall RJ. The use of classification and regression trees in clinical epidemiology. J Clin Epidemiol 2001; 54: 603-609.
18. Radespiel-Tröger M, Rabenstein T, Schneider HT, Lausen B. Comparison of tree-based methods for prognostic stratification of survival data. Artif Intell Med 2003; 28: 323-341.
19. LeBlanc M, Crowley J. Relative risk trees for censored survival data. Biometrics 1992; 48: 411-425.
20. Davis RB, Anderson JR. Exponential survival trees. Stat Med 1989; 8: 947-961.
21. Crichton NJ, Hinde JP, Marchini J. Models for diagnosing chest pain: is CART helpful? Stat Med 1997; 16: 717-727.
22. Harrell FE Jr. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer 2001.
23. Nichols CR, Catalano PJ, Crawford ED et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998; 16: 1287-1293.
24. Nichols CR, Williams SD, Loehrer PJ et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991; 9: 1163-1172.
25. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees. Belmont, CA: Wadsworth 1984.
26. Harrell FE Jr, Lee KL, Califf RM et al. Regression modelling strategies for improved prognostic prediction. Stat Med 1984; 3: 143-152.
27. Grunkemeier GL, Jin R. Receiver operating characteristic curve analysis of clinical risk models. Ann Thorac Surg 2001; 72: 323-326.
28. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. London: Chapman & Hall, Inc 1993.
29. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
30. Steyerberg EW, Eijkemans MJ, Harrell FE Jr, Habbema JD. Prognostic modeling with logistic regression analysis: in search of a sensible strategy in small data sets. Med Decis Making 2001; 21: 45-56.
31. Bokemeyer C. Current trends in chemotherapy for metastatic non-seminomatous testicular germ cell tumors. Oncology 1998; 55: 177-188.
32. Fizazi K, Kramar A, Culine IC et al. The early decline of tumor markers predicts outcome in poor prognosis non-seminomatous germ-cell tumors (NSGCT): results of a multi-institution study. Proc Am Soc Clin Oncol 2002; 21: 185a (Abstr 739).
33. Mazumdar M, Bajorin DF, Bacik J et al. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 2001; 19: 2534-2541.
34. Heidenreich A, Srivastava S, Moul JW, Hofmann R. Molecular genetic parameters in pathogenesis and prognosis of testicular germ cell tumors. Eur Urol 2000; 37: 121-135.
35. Donadio AC, Bosl GJ. The future of therapy for nonseminomatous germ cell tumors. Chest Surg Clin N Am 2002; 12: 769-789.